<DOC>
	<DOC>NCT01208155</DOC>
	<brief_summary>Study in healthy males to assess bioavailability of 4 different fostamatinib tablets</brief_summary>
	<brief_title>Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets</brief_title>
	<detailed_description />
	<criteria>Weight of at least 50 kg and body mass index (BMI) between 18.0 and 35.0 kg/m2 inclusive Volunteers must be willing to use barrier contraception ie, condoms, from the Day 1 of Treatment Period 1 until 2 weeks after the final dosing of the investigational product (IP) History of any clinically significant disease or disorder History or presence of GI, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs (except for cholecystectomy) Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of drug Volunteers who smoke more than 5 cigarettes or the equivalent in tobacco per day Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis results as judged by the Investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Fostamatinib</keyword>
</DOC>